Back to Report Store Home

Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge To Pharmaceutical Companies

  • Published: Oct-2011
  • Report Code: GBIHC122MR
  • Report Format: pdf

Description

GBI Research's report “Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies contains a comprehensive overview of the healthcare system, and pricing and reimbursement process in 12 European nations with a detailed analysis of the different regulatory mechanisms used in these countries. The report closely scrutinizes the major changes in the pharmaceuticals related pricing and reimbursement in these European nations in the recent past and their impact in the near future. The countries analyzed in the report are the top five countries of Europe, Eastern European countries such as Czech Republic, Poland, Romania and Hungary as well as Scandinavian countries such as Norway, Finland and Denmark.

Scope

  • Detailed study of the healthcare systems and roles of the key players in the respective pharmaceutical systems of top five countries of Europe – the UK, France, Germany, Italy and Spain; Eastern European countries of Czech Republic, Poland, Hungary, and Romania; and Scandinavian countries of Norway, Denmark and Finland.

  • Analysis of the major pricing and reimbursement mechanisms in each country.

  • Key trends that follow from the recent changes brought about in the pricing and reimbursement mechanism.

  • Build an understanding of the possible major challenges brought about by the enactment of changes in the pricing and reimbursement scene in the countries covered.

Reasons To Buy

  • Build understanding of the pharmaceuticals related key pricing and reimbursement mechanisms in the key markets of Europe.

  • Optimize your investment through identification and understanding of the changes in the pharmaceuticals regulatory mechanism in the economies.

  • Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in pricing and reimbursement scene for the countries covered.

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3500
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7000
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$10500
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards